Pentwater Capital Management 13F: Cuts KVUE Stake by $90M

Pentwater Capital Management Reduces Kenvue Inc. Holdings

Pentwater Capital Management trimmed its investment in Kenvue Inc. (NYSE: KVUE) during the quarter ended May 15, 2026, according to a recent Form 13F filing with the U.S. Securities and Exchange Commission. The filing reflects holdings as of that specific reporting date and may not represent the investor's current position.

Inside Pentwater's Share Reduction

The fund cut its stake by 8.3%, selling off 4,720,600 shares during the period. Prior to the trade, Pentwater held 56,720,600 shares. The adjustment left the fund with 52,000,000 shares, which carried a reported value of about $993.7 million based on the filing details.

Kenvue Stock and Market Standing

Kenvue shares traded recently at $19.11, resting comfortably above its 200-day moving average of $18.01 and its 50-day moving average of $18.88. The stock has traded between a 52-week low of $14.02 and a 52-week high of $20.13. With a price-to-earnings ratio of 20.79, the consumer health company carries a market capitalization of roughly $33.9 billion.

Recent Earnings Performance

For the company's financial results, Kenvue reported $15.41 billion in revenue with a revenue growth rate of 3.0%. The firm posted earnings per share of $0.85, accompanied by a net margin of 10.8% and a return on equity of 15.6%. The company's next earnings report is anticipated on November 5, 2026.

Dividend Yield and Payouts

Kenvue pays an annual dividend of $0.84 per share, providing a dividend yield of 4.72%. The company's dividend payout ratio sits at 97.65%.

Analysts Set New Price Targets

Wall Street analysts maintain a consensus hold rating on the stock with a mean price target of $19.50 across 12 analyst opinions. Recent updates include UBS maintaining a neutral rating with a $19.00 target on August 11, 2026, following an earlier adjustment to $20.00 in July. Barclays also maintained an equal-weight rating with a $19.00 price target on July 21, 2026.

Understanding Kenvue's Business

Kenvue operates as a major consumer health company, providing well-known over-the-counter medicines, skin care products, and essential health items. Its vast portfolio includes household brands like Tylenol, Zyrtec, Neutrogena, and Band-Aid. Headquartered in Summit, New Jersey, the company employs over 21,000 people globally across its various self-care and health segments.

What's Ahead for Kenvue Inc.

Institutional investors like Pentwater will continue filing quarterly updates that reveal shifts in large positions. Investors watching Kenvue can monitor upcoming earnings releases and future regulatory disclosures for further clues on institutional sentiment.